On April 15, 2026 Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, reported that its FL115 Program has successfully completed technical transfer of manufacturing process and analytical methods by its manufacturing partner JOINN Biologics INC, and will soon initiate production of GMP batches to support upcoming pivotal clinical trial in nonmuscle invasive bladder cancer (NMIBC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein, of which Fbody is a single-chain Fc engineered to maintain FcRn affinity while eliminating binding of FcγRs and complement systems, aiming to optimize protein half-life and biodistribution. FL115 drug substance and drug products have demonstrated superb stability and solubility at 20 mg/ml, as well as robust GMP manufacturing process with low cost.

A clinical study of FL115 (NCT07122414) in Bacillus Calmette-Guérin (BCG) unresponsive NMIBC has been ongoing. After 1st patient dosing in August 2024, 10 patients have been dosed with FL115 alone and 42 patients have been dosed with FL115 in combination with BCG so far, all through intravesical delivery.

"We are excited about the potential best-in-class profile of FL115 in BCG unresponsive NMIBC, supported by preliminary safety and efficacy data across multiple dose-levels," said Dong Wei, Ph.D., Chief Executive Officer of Forlong Biotechnology, "we are on track to have a robust clinical data set to discuss with regulatory authorities on our pivotal clinical trial design and registration plan by end of 2026. CMC readiness is an important pillar of the FL115 program and we greatly appreciate the expertise and effort of JOINN Biologics as our manufacturing partner. Together we will advance FL115 into the pivotal clinical stage for NMIBC in 2027."

About FL115

FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein, aiming to enhance anti-tumor immunity via IL-15-mediated signaling on NK and CD8+ T cells while minimizing complexity from Fc. FL115 has demonstrated significant anti-tumor activities as a monotherapy or as part of combination therapy in vivo, and can be manufactured by a robust and efficient process with excellent product stability. Clinically, FL115 has demonstrated favorable safety profile and preliminary clinical responses as a monotherapy, and has the best-in-class potential to synergize with current and emerging T cell-targeting immunotherapies through combination therapy to significantly improve the treatment outcome for patients. It is currently being investigated in combination with Bacillus Calmette-Guérin (BCG) in a Phase 2 clinical trial to evaluate safety and preliminary efficacy in patients with nonmuscle invasive bladder cancer (NMIBC) and in combination with an anti-PD1 monoclonal antibody in a Phase 1b/2 clinical trial to evaluate safety and preliminary efficacy in patients with advanced solid tumors.

(Press release, Forlong Biotechnology, APR 15, 2026, View Source [SID1234664422])

On April 15, 2026 TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, reported one oral and three poster presentations regarding the Company’s clinical asset, TRI-611, as well as its preclinical asset Cyclin E1 (CCNE1) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TRIANA will present data highlighting the first-in-class clinical stage compound TRI-611 as a selective, brain-penetrant molecular glue degrader for the treatment of anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). In pre-clinical ALK+ NSCLC tumor models, TRI-611 promotes the degradation of tyrosine kinase inhibitor (TKI)-sensitive and -resistant ALK fusion proteins and leads to regression of both ALK TKI-refractory subcutaneous and intracranial tumors. TRI-611 demonstrates combinability with ALK TKIs in pre-clinical tumor models, potentially opening additional therapeutic avenues for patients with ALK+ NSCLC.

"We are pleased to provide further preclinical data highlighting the breadth of our molecular glue degrader therapeutics portfolio," said Dr. Patrick Trojer, President and CEO of TRIANA. "By binding at a site distal to the TKI domain binding site, TRI-611 tethers the E3 ligase complex cereblon to ALK fusion proteins, promoting their destruction by engaging the cell’s own degradation machinery. This mechanism renders potent tumor regression activity, irrespective of mutations in the TKI binding domain."

Oral Presentation Details:

Title:

TRI-611, a potent, selective, CNS-penetrant ALK molecular glue degrader for the treatment of ALK-fusion protein positive non-small cell lung cancer

Abstract Number:

ND07

Date and Time:

Sunday, April 19, 2026, 3:45 p.m. – 4:00 p.m. PT

Session Category:

New Drugs on the Horizon: Part 2

Session:

DDT02

Location:

Ballroom 20 CD – Upper Level – Convention Center

Poster Presentation Details:

Title:

TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors

Abstract Number:

5787 / 14

Date and Time:

Tuesday, April 21, 2026, 2:00 p.m. – 5:00 p.m. PT

Session Category:

Proximity-Induced Drug Discovery 2

Session:

T09.04

Location:

Poster Section 15

Title:

TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases​

Abstract Number:

4618 / 28

Date and Time:

Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PT

Session Category:

Proximity-Induced Drug Discovery 1

Session:

ET09.03

Location:

Poster Section 18

Title:

Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers

Abstract Number:

5789 / 16

Date and Time:

Tuesday, April 21, 2026, 2:00 p.m. – 5:00 p.m. PT

Session Category:

Proximity-Induced Drug Discovery 2

Session:

ET09.04

Location:

Poster Section 15

About TRI-611

TRI-611 is a novel oral, small-molecule, investigational therapy designed to target and degrade ALK fusion proteins in patients with ALK+ NSCLC. TRI-611 is a potent, brain-penetrant molecular glue degrader that brings ALK fusion proteins and the E3 ligase enzyme cereblon together through a unique binding mechanism that works independently of the ALK kinase active site and harnesses the body’s innate protein-degradation machinery to selectively eliminate the ALK fusion protein. TRI-611 is designed to overcome the limitations observed with currently available ALK inhibitors.

About CCNE1

CCNE1 (cyclin E1) is a key disease driver in CCNE1-amplified tumors and in a subset of HR+/HER2- breast cancers. As a critical regulator of the cell cycle, CCNE1 protein levels are tightly regulated to maintain control of cell growth in normal cells, while elevation of CCNE1 protein levels can lead to aberrant cell growth in cancer. CCNE1 has been difficult to drug with traditional approaches. Our novel oral, small-molecule molecular glue degraders of CCNE1 offer a unique approach to targeting this key cancer driver by harnessing the cell’s protein degradation machinery to substantially decrease excess CCNE1 and halt growth of CCNE1-dependent tumor cells.

(Press release, Triana Biomedicines, APR 15, 2026, View Source [SID1234664421])

On April 15, 2026 Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, reported that there will be two customer posters presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster 2421; April 20, 2026
Primary Author: Nigel O’Neil, PhD
Poster Title: Combining deep mutational scanning and next-generation protein sequencing to harness dominant protein variants to develop DNA repair inhibitors

In the first poster, the researchers describe a complementary genetic (high throughput screens) and proteomic (benchtop protein sequencing) approach to find and model the behavior of therapeutics targeting DNA repair enzymes.

Poster 7650; April 22, 2026
Primary Author: Gloria Sheynkman, PhD
Poster Title: High-resolution detection of post-translational modifications using single-molecule protein sequencing

In the second poster, the researchers demonstrated the ability to resolve and quantify multiple PTMs using Quantum-Si’s single-molecule protein sequencing technology. The authors suggested that the technology could be used to add proteoform characterization to biomarker studies, providing additional resolution not readily available in broad biomarker screening panels. The authors further concluded that they expect this technology could democratize advanced protein characterization, making the high-resolution detection of PTMs available to a broader scientific community.

"We are excited to see new customer data being presented at key industry conferences like AACR (Free AACR Whitepaper), that continue to demonstrate the power of our proprietary single-molecule protein sequencing technology," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "We invested significant effort during 2025 to build a pipeline of studies that would demonstrate the power of our technology, and we are very pleased to have a steady flow of customer pre-prints, publications and posters being released this year as we work to expand awareness and build momentum towards the launch of Proteus."

(Press release, Quantum SI, APR 15, 2026, View Source [SID1234664420])

On April 15, 2026 Zephyr AI, Inc. ("Zephyr AI"), a leader in precision medicine harnessing artificial intelligence to accelerate drug development, reported its schedule of research presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in San Diego, California, April 17-22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s posters will be presented by senior researchers and highlight novel work Zephyr AI is advancing with its biopharmaceutical and life science partners. The presentations feature multimodal AI approaches for predicting response to targeted therapies in patients with cancer, as well as checkpoint inhibitor response in patients receiving combination treatment. Across these investigations, Zephyr’s AI models operate on clinically available inputs—including liquid biopsy DNA, tissue-based molecular data, and whole-slide images—to generate drug response predictions and biological insights into tumor-intrinsic and tumor microenvironment features associated with treatment response.

"We are thrilled to showcase Zephyr AI’s work at this year’s AACR (Free AACR Whitepaper) meeting," said Zephyr AI CEO Allen Chao, PhD. "The utilization of AI with multimodal data and clinically available inputs is transforming research and accelerating discovery. This is a wonderful opportunity to share how our novel approach is helping drive important advances in cancer treatment."

Official schedule of Zephyr AI presentations at AACR (Free AACR Whitepaper):

Real world prediction and biological characterization of sotorasib sensitivity using multimodal AI and liquid biopsy genomic inputs (Presentation 5235)

Session Title: Biomarkers Predictive of Therapeutic Benefit 5
Presenter: Emily Vucic, VP Science
Session Date & Time: April 21, 9:00AM – 12:00PM
Location: Poster Section 42
Poster Board Number: 1

Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and whole-slide images with explainable tumor biology and combination therapy insights (Presentation 1014)

Session Title: Biomarkers Predictive of Therapeutic Benefit 1
Presenter: Maayan Baron, Assoc Dir of Computational Biology
Session Date & Time: April 19, 2026 2:00PM – 5:00PM
Location: Poster Section 40
Poster Board Number: 8

Leadership from Zephyr AI will be attending AACR (Free AACR Whitepaper). Please contact [email protected] to request a meeting.

(Press release, Zephyr AI, APR 15, 2026, View Source [SID1234664419])

On April 15, 2026 Agilent Technologies Inc. (NYSE: A) reported it will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode microplate readers. Cytation 9 is designed to support advanced live‑cell and endpoint assays by combining automated microscopy with conventional microplate reading in a single system, supporting a range of cell‑based research applications.

In addition, Agilent will provide an early preview of the upcoming AI‑enabled software enhancement for the xCELLigence RTCA eSight, designed to bring the same straightforward, objective data analysis long valued in impedance measurements to label‑free live‑cell imaging, while supporting more consistent, reproducible results.

AACR attendees are invited to join Agilent at the Exhibitor Spotlight Theater for a session titled "Direct Targeted Methylation Sequencing (dTMS) with SureSelect: Targeted Long‑Read Sequencing for Native Variant and Methylation Profiling in Oncology." The session will be presented by Andrew Jenkins, biotechnology research associate at Wasatch Biolabs, and will examine the use of targeted long‑read sequencing approaches in oncology research.

Agilent will also highlight its collaboration with Oxford Nanopore Technologies, demonstrating the compatibility of Agilent SureSelect target enrichment chemistry with ONT’s long-read sequencing platforms. By integrating SureSelect libraries into ONT sequencing workflows, researchers can pair hybrid-capture target enrichment with real-time, long-read sequencing to support applications such as target genomics, structural variant analysis, and methylation profiling.

Immediately preceding AACR (Free AACR Whitepaper) 2026, Agilent’s xCELLigence User Group Meeting will bring together the real-time cell analysis community to share best practices, applications, and real-world insights from functional cell-based research.

Agilent is continuing its collaboration with the AACR (Free AACR Whitepaper) Foundation following a virtual 5K fundraiser held in October 2025 that raised $15,000 and funded 14 Scholars-in-Training awards. Agilent representatives will meet scholars supported through this initiative at the AACR (Free AACR Whitepaper) Scholar‑in‑Training Award Reception and will promote the 5k fundraiser at the Agilent booth as part of its ongoing commitment to supporting early-career cancer researchers.

"At Agilent, our mission is to support advances in cancer research by providing integrated technologies and collaborative solutions," said Rita Shaknovich, chief medical officer at Agilent Technologies. "By delivering trusted answers, we aim to help researchers and clinicians make more informed decisions across the cancer research and care continuum."

Agilent will exhibit at booth No. 4527 and host additional scientific and networking events throughout the meeting.

(Press release, Agilent, APR 15, 2026, View Source [SID1234664418])